Antiviral Drugs - Gabon

Gabon

The Antiviral Drugs market in Gabon is anticipated to witness a substantial increase in revenue, with projections indicating it will reach US$1.67m in 2024.
Furthermore, it is expected to maintain a steady growth rate, with a Compound Annual Growth Rate (CAGR) of 0.94% from 2024 to 2029.
This growth is predicted to result in a market volume of US$1.75m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$30,640.00m in 2024.
Gabon is experiencing a growing demand for antiviral drugs as the country faces an increase in viral infections.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Gabon has seen significant growth in recent years.

Customer preferences: Antiviral drugs are used to treat viral infections and have become increasingly popular due to the rise of viral diseases such as HIV, Hepatitis, and Ebola. Gabon has a high prevalence of these diseases, which has led to an increase in demand for antiviral drugs.

Trends in the market: The Antiviral Drugs market in Gabon has seen a surge in demand due to the COVID-19 pandemic. The pandemic has led to an increase in awareness about antiviral drugs and their effectiveness in treating viral diseases. The government of Gabon has also taken steps to ensure the availability of these drugs to the public.

Local special circumstances: Gabon is a small country with a population of just over 2 million people. The healthcare system in Gabon is underfunded and understaffed, which has led to a shortage of healthcare professionals and medical supplies. This has made it difficult for the government to provide adequate healthcare services to the population.

Underlying macroeconomic factors: Gabon is an oil-rich country with a high GDP per capita. However, the country has been facing economic challenges due to the decline in oil prices and the COVID-19 pandemic. The government has been forced to cut spending on healthcare and other social services, which has made it difficult to provide adequate healthcare to the population.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.